Şentürk Yikilmaz Aysun, Akinci Sema, Bakanay Şule Mine, Zengin Zeynep Büşra, Dilek İmdat
1Department of Hematology, Yildirim Beyazit University, Bilkent Yolu 3. Km, Çankaya, 06010 Ankara, Turkey.
2Department of Hematology, Ataturk Training and Research Hospital, Ankara, Turkey.
Indian J Hematol Blood Transfus. 2020 Jan;36(1):84-90. doi: 10.1007/s12288-019-01169-8. Epub 2019 Aug 13.
Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive disease (Group 2). Group 1 included those who did not require any treatment since diagnosis and those who did not progress after receiving the first step anti CLL treatment. Group 2 included the patients who received ≥ 2 steps treatment. The relation between the two groups was analyzed statistically in terms of clinical, laboratory and flow cytometric findings. Twenty patients (36.3%) required treatment at the time of diagnosis, four patients (3.8%) received first-line treatment during follow-up and 31 (56.3%) patients were followed without any treatment. Thirteen patients required second step treatment after a median of 26.3 months. The risk of progression was found to be increased 5-fold ( = 0.015) in the CD38 positive patient group, 4.2-fold ( = 0.0147) in the FMC7 negative patient group and 2.8-fold in the CD11c negative patient group. FMC 7 negativity decreased total survival 5.9-fold ( = 0.051). Unlike similar publications, we found that patients with CD11c or FMC7 negativity were in a higher need for ≥ 2 step treatment. This suggests that CD11c or FMC7 negativity may be used as a poor prognostic marker in CLL.
慢性淋巴细胞白血病（CLL）是一种常见的血液系统恶性肿瘤。本研究旨在探讨临床、实验室及流式细胞术分析对CLL患者的预后影响。将55例新诊断的CLL病例分为两组，即疾病稳定组（第1组）和疾病进展组（第2组）。第1组包括自诊断以来无需任何治疗的患者以及接受第一步抗CLL治疗后未进展的患者。第2组包括接受≥2步治疗的患者。从临床、实验室及流式细胞术检查结果方面对两组之间的关系进行统计学分析。20例患者（36.3%）在诊断时需要治疗，4例患者（3.8%）在随访期间接受一线治疗，31例患者（56.3%）未接受任何治疗进行观察。13例患者在中位时间26.3个月后需要第二步治疗。发现CD38阳性患者组进展风险增加5倍（P = 0.015），FMC7阴性患者组增加4.2倍（P = 0.0147），CD11c阴性患者组增加2.8倍。FMC 7阴性使总生存期降低5.9倍（P = 0.051）。与类似出版物不同的是，我们发现CD11c或FMC7阴性的患者更需要≥2步治疗。这表明CD11c或FMC7阴性可能作为CLL的不良预后标志物。
